These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21218756)

  • 41. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM; McIntyre L; Bernard L; Fendrick AM
    Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endoscopic reflux esophagitis in patients with upper abdominal pain-predominant dyspepsia.
    Song HJ; Choi KD; Jung HY; Lee GH; Jo JY; Byeon JS; Yang SK; Hong WS; Kim JH
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2217-21. PubMed ID: 18031384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children.
    Hassall E
    J Pediatr; 2005 Mar; 146(3 Suppl):S3-12. PubMed ID: 15758900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
    Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
    J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
    Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
    Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
    Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?
    Tack J; Fass R
    Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():28-34. PubMed ID: 14725576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
    Kinoshita Y; Hongo M;
    Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A false sense of security; symptom control does not predict healing of oesophagitis on proton pump inhibitors.
    Tan VP; Wong BC
    Aliment Pharmacol Ther; 2009 Aug; 30(3):307-8; author reply 308-9. PubMed ID: 19624463
    [No Abstract]   [Full Text] [Related]  

  • 58. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastroesophageal reflux disease with laryngopharyngeal manifestation in Korea.
    Park JH; Lee DH; Kim JY; Park SY; Yoon H; Park YS; Kim N; Jeong SH; Kim JW; Lee SH; Hwang JH; Jung HC
    Hepatogastroenterology; 2012; 59(120):2527-9. PubMed ID: 23178619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional heartburn and non-erosive reflux disease.
    Savarino V; Savarino E; Parodi A; Dulbecco P
    Dig Dis; 2007; 25(3):172-4. PubMed ID: 17827934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.